Cas12a chRDNA-mediated in vivo genome editing for high specificity functional gene disruption
Molecular Therapy Nucleic Acids. Pre-publication draft online September 2, 2026
Off-the-shelf CAR-T cell therapies
CAR-T cell therapies have shown great promise in treating blood cancers and autoimmune diseases. Our CAR-T cell therapies are armored for potentially improved activity against diseases and are designed to reach a broad number of patients with off-the-shelf treatment options.
Scientific publications
Recent publications
CB-011, an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking, in patients with relapsed/refractory multiple myeloma
European Hematology Association (EHA) 2026 Hybrid Congress, June 14, 2026
Vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout, in patients with relapsed/refractory B cell non-Hodgkin lymphoma
European Hematology Association (EHA) 2026 Hybrid Congress, June 12, 2026
chRDNA and CRISPR
Cas12a chRDNA-mediated in vivo genome editing for high specificity functional gene disruption
Molecular Therapy Nucleic Acids. Pre-publication draft online September 2, 2026
Cas12a CRISPR Hybrid RNA-DNA (chRDNA)-Mediated In Vivo Genome-Editing Technology for Efficient and Functional Hepatic Gene Disruption
American Society of Cell & Gene Therapy (ASGCT) Annual Meeting, May 7-11, 2024.
Improved genome editing with Cas12a and Cas9 chRDNA platform in T, NK, B, and iPS cells
Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®. February 21-24, 2024.
Conformational control of Cas endonucleases by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells
Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT). May 16, 2022.
Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells
Molecular Cell. September 2, 2021.
Harnessing type I CRISPR–Cas systems for genome engineering in human cells
Nature Biotechnology. November 18, 2019.
Advances in industrial biotechnology using CRISPR-Cas systems
Trends in Biotechnology. February 1, 2018.
Mapping the genomic landscape of CRISPR-Cas9 cleavage
Nature Methods. May 1, 2017.
DNA repair profiling reveals nonrandom outcomes at Cas9-mediated breaks
Molecular Cell. August 4, 2016.
Guide RNA functional modules direct Cas9 activity and orthogonality
Molecular Cell. October 16, 2014.
Vispa-cel
Vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout, in patients with relapsed/refractory B cell non-Hodgkin lymphoma
European Hematology Association (EHA) 2026 Hybrid Congress, June 12, 2026
Encore: A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) for relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial
European Hematology Association (EHA) 2024 Hybrid Congress, June 13, 2024.
CB-010 ANTLER Phase 1 trial: Results from dose escalation phase
iwCAR-T Meeting. April 20, 2024.
Deep and durable response in a patient with primary refractory DLBCL treated with CB-010, CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (Antler Trial)
EBMT/EHA CAR T Cell Meeting. February 15-17, 2024.
Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness
Cytotherapy. Published online April 21, 2023.
A First-in-Human Phase 1, Multicenter, Open-label Trial of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B cell Non-Hodgkin Lymphoma (ANTLER Trial)
64th American Society of Hematology (ASH) Annual Meeting. December 10-13, 2022.
CRISPR-edited Allogeneic Anti-CD19 CAR-T Cell Therapy with PD-1 Knockout Induces Prolonged Complete Response in Relapsed/Refractory Follicular Lymphoma Patient: Case Report from CB-010 ANTLER Trial
Lymphoma, Leukemia, & Myeloma Congress. October 18-22, 2022.
First-in-Human Trial of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knock Out, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)
European Hematology Association (EHA) 2022 Hybrid Congress. June 10, 2022.
CB-011
CB-011, an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking, in patients with relapsed/refractory multiple myeloma
European Hematology Association (EHA) 2026 Hybrid Congress, June 14, 2026
High-specificity CRISPR-mediated genome engineering in anti-BCMA allogeneic CAR T cells suppresses allograft rejection in preclinical models
Cancer Immunology Research. February 9, 2024.
A first-in-human Phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CaMMouflage trial)
American Society of Clinical Oncology (ASCO) Annual Meeting. June 5, 2023.
CB-011, a BCMA-specific allogeneic CAR-T cell therapy, engineered with next-generation CRISPR technology to knock out B2M and express myelomar/r multiple transgene to blunt immune cell-mediated rejection, for B2M–HLA-E fusion
TANDEM MEETINGS: Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®. February 15-19, 2023.
A BCMA-specific allogeneic CAR-T cell therapy (CB-011) genome-engineered to express an HLA-E fusion transgene to prevent immune cell rejection
American Association for Cancer Research (AACR) Annual Meeting. April 10, 2022.
Other
Preclinical evaluation of CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, that exhibits specific and potent cytotoxicity in acute myeloid leukemia (AML) xenograft models
American Association for Cancer Research (AACR) Annual Meeting. April 9, 2024.
CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy engineered with next-generation CRISPR technology to resist both the immunosuppressive tumor microenvironment and immune cell-mediated rejection, for patients with relapsed or refractory acute myeloid leukemia
American Association for Cancer Research (AACR) Annual Meeting. April 17, 2023.
CB-020, an Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic CAR-NK Cell Therapy, Engineered for Enhanced Activity Against Solid Tumors
12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research – Translating Knowledge into Practice. December 10-14, 2022.
